Medical Condition News

RSS

New diabetes education program brings better blood sugar control

An intensive program that taught low-income, poorly educated diabetics to better manage their disease resulted in significantly improved long-term blood sugar control, according to Johns Hopkins researchers who designed and implemented the program.

11 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

Vanda initiates Fanapt Phase I study in patients with schizophrenia

Vanda Pharmaceuticals Inc. announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable formulation of Fanapt.

11 Apr 2011

OFID honors UAE ear surgeon with Annual Award for Development

The Director-General of the OPEC Fund for International Development, Mr. Suleiman J. Al-Herbish, today announced Dr. Mazen Al-Hajri as the recipient of the 2011 OFID Award for Development.

11 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.

11 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Study shows how specific nutritional combination may help maintain healthy breast tissue

Researchers from Canada and the United States today told attendees of the Experimental Biology 2011 Scientific Meeting that they have uncovered a possible means of enabling women to favorably influence whether the estrogens in their bodies take a "beneficial path" or a "disease-potential" path.

11 Apr 2011

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.

11 Apr 2011

NBCAM events increase breast cancer diagnosis

Each October, the color pink marks the arrival of National Breast Cancer Awareness Month. Media coverage, product promotions and even the football gridirons showcase the national effort to promote screenings and early detection of the cancer that 200,000 American women are diagnosed with each year.

11 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

Study: Patients with glaucoma experience psychological problems

Fear of the unknown is one of the greatest issues facing patients with glaucoma - the second leading cause of blindness worldwide after cataracts - according to research in the April issue of the Journal of Advanced Nursing. People also worry about how the eye disease, which can be hereditary, will affect other members of their family.

11 Apr 2011

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

The Canadian Association of PNH Patients welcomes the upcoming publication of a study that resoundingly proves the efficacy of Soliris, the first and only life-saving treatment for the ultra-rare blood disease known as Paroxysmal Nocturnal Haemoglobinuria.

11 Apr 2011

CINJ experts to comment on vaccine therapy and biomedical informatics

April marks National Cancer Control Awareness Month, which focuses on the importance of prevention, treatment, and research. Making significant contributions in all of these areas is The Cancer Institute of New Jersey, one of the nation's 40 Comprehensive Cancer Centers as designated by the National Cancer Institute and the only such center in New Jersey.

11 Apr 2011

New experimental drug can help treat peripheral neuropathy in cancer patients

Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment.

11 Apr 2011

Tai chi, green tea may help reduce inflammatory diseases in postmenopausal women

C.S. Lewis, the famous author and Oxford academic, once proclaimed "You can't get a cup of tea big enough or a book long enough to suit me." We sip it with toast in the morning, enjoy it with sweets and biscuits in the afternoon, and relax with it at the end of the day.

11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor that plays an important role in the pathology of central nervous system disorders.

11 Apr 2011

Planned Parenthood funding a major stumbling block in budget negotiations

On the brink of a painful government shutdown, the Obama administration readied furlough notices for hundreds of thousands of workers Friday as Republican and Democratic leaders accused each other of refusing to give ground on a deal to keep operations running. ... Senate Majority Leader Harry Reid accused the Republicans of blocking a compromise because they were determined to make it harder 'for women to get cancer screenings' -- a Planned Parenthood funding reference.

11 Apr 2011

Neurosurgeons to present techniques and discuss surgical approaches at AANS meeting

Neurosurgeons from NYU Langone Medical Center will present techniques and discuss surgical approaches and applications of technology at the annual meeting of the American Association of Neurological Surgeons, held April 9-13, 2011 at the Colorado Convention Center in Denver.

11 Apr 2011